Leonlimab (PRO 140) Phase II clinical trial program for the treatment of new coronary pneumonia obtains IND
-
Last Update: 2020-06-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
CytoDyn, a biotech company that develops leronlimab (PRO 140) (CCR5 antagonist with the potential for multiple indications) and today announced that it has submitted a research application (IND) to the FDA for a Phase II clinical trial of leronb (PRO 140) to verify the effectiveness and safety of the treatment of THE COLIMAlima (PRO 140) for complications of CODilima(140)early studies have shown that Leronlimab inhibits the migration of Treg to inflammatory areas, and Tregs inhibits the innate immune response to pathogensMost importantly, macrophage migration and the release of inflammatory cytokines, including TNF, are responsible for severe lung damage in some patients, and the combination of Leronlimab and CCR5 alters macrophage migration and cytokine productionacute respiratory distress syndrome (ARDS) usually affects the entire lungs, while common pneumonia usually affects only a portion of the lungs"We believe that leronlimab can reduce the inflammation that causes ARDS, potentially reducing mortality in patients with COVID-19," said DrNader Pourhassan, President and CEO of CytoDyn
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
